Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2016-09-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds related to a company's IPO. It details the amount of funds raised, the opening of a special account for these funds, and the responsibilities of the parties involved in supervising the use of these funds. There is no financial statement or comprehensive financial report included. The document is a formal announcement about a capital raising and fund management agreement, not a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS.
2016-09-06 Chinese
关于《郑州安图生物工程股份有限公司关于股票交易异常波动有关事项的问询函》的回函
Regulatory Filings
2016-09-06 Chinese
公司章程
Regulatory Filings
2016-08-30 Chinese
首次公开发行股票上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement" for Autobio Diagnostics Co., Ltd. It contains detailed information about the company's stock listing on the Shanghai Stock Exchange, including stock code, issuance details, shareholder lock-up commitments, profit distribution policies, stock price stabilization plans, and financial data audited by an accounting firm. The document includes extensive financial statements and data, but it is primarily focused on the announcement and details of the company's initial public offering (IPO) and stock listing rather than being a full annual or interim report. The document is lengthy (15,000 characters) and contains substantive financial data, but the core purpose is to announce the company's stock listing and related commitments and policies. This type of document corresponds to a Capital/Financing Update (CAP) as it relates to the company's fundraising and capital market activities through the IPO and stock listing. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), nor is it a simple announcement of a report (RPA). Therefore, the best classification is Capital/Financing Update (CAP).
2016-08-30 Chinese
首次公开发行股票发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an announcement of the results of the initial public offering (IPO) of shares by Zhengzhou Antu Bioengineering Co., Ltd. It details the number of shares issued, subscription statistics, underwriting arrangements, and payment information. The document does not contain financial statements or detailed financial performance data but rather reports on the outcome of a capital issuance event. This fits the category of a Capital/Financing Update, as it provides information on the company's fundraising activity through the issuance of new shares.
2016-08-24 Chinese
首次公开发行股票网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 郑州安图生物工程股份有限公司. It includes information about the offline preliminary allotment results, online lottery results, subscription details, allocation proportions, and instructions for investors regarding payment and compliance. The document references regulatory approval from the China Securities Regulatory Commission and details the share issuance process, including the number of shares issued, pricing, and allocation to different investor categories. This type of document is a formal announcement of the results of a share issuance and subscription process, which fits the category of Capital/Financing Update (CAP). It is not a full financial report, earnings release, or regulatory filing unrelated to financing. The document length is substantial and contains detailed allocation data, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the best classification is CAP with high confidence.
2016-08-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.